More recently, studies in humans with type 2 diabetes have shown that low‐dose gliclazide, which does not stimulate insulin secretion at low glucose levels, augments insulin secretion in response to oral, but not intravenous, glucose.13 The gene discussed is INS; the disease is type 2 diabetes mellitus.